WORCESTER, Mass. and TORONTO, Oct. 1, 2015
WORCESTER, Mass. and TORONTO, Oct. 1, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. (www.cannsci.com) for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
The white paper is authored by Dr. Lakshmi P. Kotra, B. Pharm. (Hons), Ph.D. and Dr. Angelica M. Bello. Dr. Kotra is the Director at the Center for Molecular Design and Preformulations (CMDP) at University Health Network (UHN) in Toronto, Canada, a scientist and principal investigator at UHN, and an Associate Professor of Medicinal Chemistry at the Leslie Dan Faculty of Pharmacy, University of Toronto (http://www.uhnresearch.ca/kotralab). Dr. Bello is a scientific associate at UHN.
The white paper may be viewed online on the Generex website.
The white paper builds upon the recently announced formalization of the Co-Development and Technology Licensing Agreement between Generex and CannScience pursuant to which Generex has licensed its proprietary RapidMist™ drug delivery platform technologies to CannScience for product co-development and commercialization.
The white paper highlights the resurgent interest in the pharmacologic activity of active ingredients extracted from cannabis and the application thereof to the adjuvant treatment of a myriad of medical conditions. The paper also notes the consequent global trend toward legalization of the production and distribution of cannabis for medical purposes.
The paper describes the extraction of cannabis concentrates and references the work of CannScience to develop extraction protocols and optimal delivery formulations and the role being played by the Generex RapidMist™ drug delivery technologies. The objective of the Generex – CannScience co-development arrangements is to bring together a comprehensive set of proprietary tools to provide efficacious and dose-specific medicinal cannabis in a safe and simple manner to patients as a solution to the problems of dose control, bioavailability, and safety risks associated with smoking and edibles.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/generex-announces-issuance-of-buccal-cannabis-white-paper-300152469.html
SOURCE Generex Biotechnology Corporation